skip to main content

News Archive

Date: 11/29/2023
Rogel Cancer Center faculty and trainees will lead more than three dozen presentations, posters and moderated sessions at the American Society of Hematology 2023 annual meeting. This year’s meeting will be held in-person and virtually in San Diego, California. Find a list of U-M presenters and other resources for attendees.
Date: 11/29/2023
Everyone has a story. And those stories help show the different influences on each person’s life, helping to build empathy, challenge stereotypes and create a more inclusive environment. That’s the basis of a new DEI initiative the Rogel Oncology Clinical Trials Support Unit, or OCTSU, has started. DEI Storytelling gives a platform for team members to share their personal journey, anecdotes or reflections, with an emphasis on topics that may not be widely understood by all staff.
Date: 11/20/2023
For men with a type of low-risk early prostate cancer, surveillance can be an option over immediate treatment. To help providers and patients make more informed decisions about safely choosing surveillance, Rogel Cancer Center researcher Simpa Salami, M.D., M.P.H., received a $1.14 million grant from the National Cancer Institute to answer lingering questions about the biology of these early prostate cancers.
Date: 11/09/2023
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
Date: 10/16/2023
Every year, health plans offer open enrollment – a time to reassess your benefits and select new options. But is it worth the hassle to change plans? For people with expensive prescription drugs, switching plans could save them thousands of dollars in copays. And a simple tool can help people easily compare out-of-pockets expenses for anyone with a Medicare Part D prescription plan.
Date: 10/13/2023
University of Michigan Health will purchase the Edison platform used to deliver histotripsy, a technology pioneered at the university that uses sound waves to destroy tissue. HistoSonics, a company co-founded by U-M faculty, received approval this week from the U.S. Food and Drug Administration to use histotripsy via the Edison platform in liver treatment.
Date: 10/12/2023
The annual hospital review included the cancer center on their list of elite programs around the county.
Date: 10/09/2023
Pioneered at the University of Michigan, histotripsy offers a promising alternative to cancer treatments such as surgery, radiation and chemotherapy, which often have significant side effects. Today, FDA officials awarded clearance to HistoSonics, a company co-founded in 2009 by U-M engineers and doctors for the use of histotripsy to destroy targeted liver tissue.
Date: 09/26/2023
A gene sequencing method called ribosome profiling has expanded our understanding of the human genome by identifying previously unknown protein coding regions. Also known as Ribo-seq, this method allows researchers to get a high-resolution snapshot of protein production in cells.
Date: 09/20/2023
Rogel Cancer Center faculty and trainees will lead more than 20 presentations, posters and moderated sessions at ASTRO 2023 held October 1-4, at the San Diego Convention Center, San Diego, CA.